Access, SpePharm in European MuGard pact
This article was originally published in Clinica
Executive Summary
Dallas, Texas-based Access Pharmaceuticals has signed an agreement which will see its oral wound rinse product MuGard marketed in Europe by Dutch company SpePharm. The agreement incorporates the European Union plus Switzerland, Norway and Iceland, and will see SpePharm become responsible for manufacturing and regulatory approval of the product within this territory.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.